Showing results (231-240 of 240) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 240 results.
Virchows Archiv : an International Journal of Pathology|July 23, 2024
The clinicopathological and prognostic significance of autonomic nerves in salivary duct carcinomaManami Kajiwara, Hideaki Takahashi, Masato Nakaguro, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 9, 2025
Cytoplasmic p53 Immunostaining in Salivary Duct Carcinoma: A Poor Prognostic Factor Associated With Characteristic TP53 VariantsYoshitaka Utsumi, Masato Nakaguro, Daisuke Kawakita, et al.
Oncotarget|February 9, 2018
Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomasTomotaka Shimura, Yuichiro Tada, Hideaki Hirai, et al.
Virchows Archiv : an International Journal of Pathology|February 28, 2020
The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinomaHideaki Hirai, Yuichiro Tada, Masato Nakaguro, et al.
Modern Rheumatology|October 10, 2025
Comparative Effectiveness and Safety of Peficitinib and Abatacept for Rheumatoid Arthritis: A Multicenter, Inverse Probability Weighting AnalysisKento Ichikawa, Yosuke Kunishita, Satoru Shinoda, et al.
Frontiers in Immunology|September 18, 2023
Protective effect of hydroxychloroquine on infections in patients with systemic lupus erythematosus: an observational study using the LUNA registryChiharu Hidekawa, Ryusuke Yoshimi, Yusuke Saigusa, et al.
Frontiers in Oncology|February 21, 2022
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted TherapyNatsuki Saigusa, Hideaki Hirai, Yuichiro Tada, et al.
Oral Oncology|April 19, 2025
The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapySatoshi Kano, Daisuke Kawakita, Yoshitaka Honma, et al.
NPJ Precision Oncology|November 5, 2022
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profilingShinji Kohsaka, Yuichiro Tada, Mizuo Ando, et al.
Therapeutic Advances in Medical Oncology|September 12, 2022
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinomaDaisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, et al.
Pageof 24